NCT01919619View on ClinicalTrials.gov

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 4, 2013

Primary Completion Date

May 3, 2024

Study Completion Date

May 3, 2024

Conditions

B-Cell Non-Hodgkin LymphomaHematopoietic and Lymphoid Cell NeoplasmLeukemiaLymphomaPlasma Cell MyelomaT-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Ipilimumab

Given IV

DRUG

Lenalidomide

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01919619 - Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | Biotech Hunter | Biotech Hunter